8.00 Registration & Coffee
8:50 am Chair’s Opening Remarks
Analyzing the Landscape: Cell-Based vs Antibody-Based Anti-BCMA Therapies
9:00 am Autologous BCMA Cell Therapies for the Treatment of Multiple Myeloma
9:30 am Advances in Antibody-Based Immunotherapy in Multiple Myeloma
Synopsis
- Myeloma is still not curable
- Novel immunotherapies will improve patient outcome
- Off-the-shelf bispecific antibodies are ideally suited for wide spread clinical applications
10:00 am Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?
Synopsis
- Navigating the current treatment landscape of multiple myeloma
- Bispecifics vs ADCs: Looking at PFS data?
- Can you compare cell-based vs antibody-based, based on combination rationale?
- Response, Efficacy, PFS, OS?
- Discussing BCMA’s potential and limitations; can we become curative?
- Gathering early clinical information to form robust translational outcomes
- Discussing the effect of extramedullary disease: should we sub-classify multiple myeloma?
- What are the implications of BCMA loss for the different modalities?
- Combination, anti-CD38 and line of therapy potentials and rationale for different modalities?
- Clinical presentations discussion: extramedullary disease, neutropoenia, lymphoid issues, parkinsonian-like symptoms, prophylaxis, hypogammaglobinaemia
10.30 Speed Networking
Optimizing Preclinical Models & Translational Data: Mechanistic Understanding of Disease & Resistance
11:30 am Multiple Myeloma: A Clinical Perspective
12:00 pm Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy
Synopsis
- Exploring why mechanisms of resistance to BCMA targeted therapies require further elucidation
- Understanding the impact of BCMA antigen density on response, needing to be further characterized
- Discussing why the approach to sequencing BCMA targeting agents may require careful consideration
12.30 Lunch
Optimizing Clinical Practice: Patient Selection, Biomarkers & Toxicities
1:30 pm Toxicity to CAR-T Cell Therapy; When You’ve Seen One CAR-T Cell Patient You’ve Seen One CAR-T Cell Patient
Synopsis
- Understanding the future of the various modalities, combinations and treatment regimes
- Delving into the toxicities: neurotox, CRS and more
- Exploring allogeneic CAR’s
- Exposing long term toxicities
Development of Novel BCMA-Targeted Therapies & BCMA Beyond Multiple Myeloma
2:00 pm BCMA-ATAC: Updates on a Novel Mode of Action in Cancer Therapy
2.30 Afternoon Refreshments & Networking
3:30 pm Allogeneic BCMA CAR-T Cell Therapy for the Treatment of Multiple Myeloma
Synopsis
- Developing the first allogeneic cell therapy for R/R multiple myeloma – from
bench to bedside - Enhancing potency and persistence of allogeneic BCMA CAR-T cells with TurboCARs
- Testing the promise of TurboCAR technology in the clinic
4:00 pm Disrupting Conventional Approaches to CAR-T Cell Therapies with our Proprietary Technology Platform—FasTCAR
Synopsis
- Exploring CD19/BCMA CAR-T for treating B-cell Non-Hodgkin Lymphoma and CD19 CAR-T for treating Adult Acute Lymphoblastic Leukemia
- Latest data, potential and future direction
4:30 pm The Potential of Repurposing BCMA-Targeted Biologics for Treating Autoimmune Diseases
Synopsis
- Understanding the multitude of unmet medical needs which could be addressed with a BCMA-targeted biologic
- Exploring how the pharmacology of antibodies can be similar in healthy volunteers, autoimmune and oncology patients
- Learning how antibodies which are effective in treating hematopoietic malignancies have also been re-purposed for the effective treatment of autoimmune diseases